1 min read

ID: 3918

Discovery Date: 21 August 2021, 16:04:26 UTC

Published Date: 2021-08-20 23:00:00

Source: BioMedCentral

Link: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02542-z

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: true


AbstractNovel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2. The virus causes an exaggerated immune response, resulting in a cytokine storm and acute respiratory distress syndrome, the leading cause of COVID-19-related mortality and morbidity. So far, no therapies have succeeded in circumventing the exacerbated immune response or cytokine storm associated with COVID-19. Mesenchymal stem cells (MSCs), through their immunomodulatory and regenerative activities, mostly mediated by their paracrine effect and extracellular vesicle production, have therapeutic potential in many autoimmune, inflammatory, and degenerative diseases. In this paper, we review clinical studies on the use of MSCs for COVID-19 treatment, including the salutary effects of MSCs on the pathophysiology of COVID-19 and the immunomodulation of the cytokine storm. Ongoing clinical trial designs, cell sources, dose and administration, and populations are summarized, and the paracrine mode of benefit is discussed. We also offer suggestions for optimizing MSC-based therapies, including genetic engineering, strategies for cell surface modification, nanotechnology applications, and combination therapies.

Noun Phrases in Title

  • Mesenchymal stem cell-based therapy
  • exosomes
  • COVID-19
  • current trends
  • prospects
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.